Effects of coenzyme q10 supplementation on serum lipoproteins, plasma fibrinogen, and blood pressure in patients with hyperlipidemia and myocardial infarction

Abstract EN

Background : Low plasma concentrations of coenzyme Q10 (CoQ10) have been associated with concentration of lipoproteins and other factors contributing to coronary heart diseases.

Objectives : The present investigation aimed to improve the blood pressure and serum lipoproteins concentration in patients with myocardial infarction (MI) by CoQ10 supplementation.

Patients and Methods : In this randomized double-blinded controlled clinical trial, 52 Iranian patients with hyperlipidemia and MI were recruited to examine the effect of CoQ10 on serum total cholesterol (TC), LDL-C, HDL-C, triglyceride (TG), LDL-C / HDL-C ratio, TC / HDL-C ratio, fibrinogen, systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Individuals were randomly allocated to two groups for receiving either 200 mg / d of CoQ10 or placebo for 12 weeks.

Results : There were not significant differences in serum LDL-C (2.70 ± 0.31 vs.

2.70 ± 0.35 mmol / L), TC (4.47 ± 0.33 vs.

4.93 ± 0.57 mmol / L), TG (2.48 ± 0.12 vs.

2.25 ± 0.69 mmol / L), and fibrinogen (2.08 ± 0.99 vs.

38.7 ± 0.64 mg / dL) between CoQ10 and placebo groups.

After 12 weeks, a significant enhancement in serum HDL-C (1.44 ± 0.18 vs.

1.14 ± 0.18 mmol / L) level was observed between groups after the supplementation (P < 0.001).

A significant reduction of TC, LDL-C, and fibrinogen and a significant increase in HDL-C concentration was observed in CoQ10 group after intervention (P < 0.001).

Our assessment demonstrated statistically significant differences between the two groups in SBP and DBP after intervention (P < 0.001).

ANCOVA also revealed significant differences in the ratio of LDL-C / HDL-C and TC / HDL-C between the two groups (1.89 ± 0.42 vs.

2.39 ± 0.38, P = 0.002 ; and 3.2 ± 0.5 vs.

4.24 ± 0.66, P = 0.01, respectively).

A significant reduction of LDL-C / HDL-C and TC / HDL-C was observed in CoQ10 group (P < 0.001).

Conclusions : Twelve-week supplementation with CoQ10 in patients with hyperlipidemia and MI can improve blood pressure, serum HDL-C as well as LDL-C / HDL-C and TC / HDL-C ratios ; therefore, it might decrease the risk of frequent MI.